It has been recently postulated that the CCDC6 impairment derived from its truncation in fusion oncogenes, enhances tumour progression and impacts on selective response to therapeutics offering new chances for a tailored therapy and novel challenges to overcome drug resistance [118]. The gene discussed is CCDC6; the disease is neoplasm.